184 related articles for article (PubMed ID: 23726533)
1. Expanding the paradigm of eosinophilic esophagitis: mast cells and IL-9.
Wang YH; Hogan SP; Fulkerson PC; Abonia JP; Rothenberg ME
J Allergy Clin Immunol; 2013 Jun; 131(6):1583-5. PubMed ID: 23726533
[No Abstract] [Full Text] [Related]
2. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.
Otani IM; Anilkumar AA; Newbury RO; Bhagat M; Beppu LY; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2013 Jun; 131(6):1576-82. PubMed ID: 23623266
[TBL] [Abstract][Full Text] [Related]
3. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
5. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
6. As Easy as EoE: A Novel and Effective Multidisciplinary Approach to Care of Patients with Eosinophilic Esophagitis in the Age of Biologics.
Chawla K; Alabbas B; Sheth D; Papademetriou M
Dig Dis Sci; 2020 Aug; 65(8):2196-2202. PubMed ID: 32519139
[No Abstract] [Full Text] [Related]
7. Eosinophilic esophagitis.
Dellon ES
Gastroenterol Clin North Am; 2013 Mar; 42(1):133-53. PubMed ID: 23452635
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus S; Straumann A; Simon HU
J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
[No Abstract] [Full Text] [Related]
9. Strategies for the Use of Dupilumab in Eosinophilic Esophagitis.
Sauer BG; Barnes BH; McGowan EC
Am J Gastroenterol; 2023 May; 118(5):780-783. PubMed ID: 36716447
[No Abstract] [Full Text] [Related]
10. Dupilumab in Patients with Eosinophilic Esophagitis.
Greuter T; Schoepfer AM
N Engl J Med; 2023 Mar; 388(10):955-956. PubMed ID: 36884332
[No Abstract] [Full Text] [Related]
11. The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.
Nhu QM; Chiao H; Moawad FJ; Bao F; Konijeti GG
Am J Gastroenterol; 2018 Aug; 113(8):1261-1263. PubMed ID: 29895980
[No Abstract] [Full Text] [Related]
12. Dupilumab in Patients with Eosinophilic Esophagitis. Reply.
Dellon ES; Rothenberg ME; Bredenoord AJ
N Engl J Med; 2023 Mar; 388(10):956-957. PubMed ID: 36884333
[No Abstract] [Full Text] [Related]
13. Dupilumab for the Treatment of Adult and Adolescent Patients With Eosinophilic Esophagitis.
Trogen B; Baker MG
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2618-2619. PubMed ID: 37558363
[No Abstract] [Full Text] [Related]
14. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
15. Efficacy of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Aziz M; Haghbin H; Gangwani M; Aziz A; Dahiya DS; Ali H; Lee-Smith W; Goyal H; Kamal F
Am J Ther; 2024 Jan-Feb 01; 31(1):e43-e45. PubMed ID: 38231581
[No Abstract] [Full Text] [Related]
16. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
17. Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma.
Oh CK; Raible D; Geba GP; Molfino NA
Inflamm Allergy Drug Targets; 2011 Jun; 10(3):180-6. PubMed ID: 21428906
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in the treatment of eosinophilic esophagitis and food allergy.
Rocha R; Vitor AB; Trindade E; Lima R; Tavares M; Lopes J; Dias JA
Eur J Pediatr; 2011 Nov; 170(11):1471-4. PubMed ID: 21809010
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.
Eskian M; Khorasanizadeh M; Assa'ad AH; Rezaei N
Clin Rev Allergy Immunol; 2018 Aug; 55(1):88-98. PubMed ID: 29234969
[TBL] [Abstract][Full Text] [Related]
20. Novel Interleukin-5 Targeted Treatment Options for Severe Eosinophilic Asthma.
Berendse J; Craig B; Gullickson E
S D Med; 2018 Jun; 71(6):274-276. PubMed ID: 30005153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
